XML 36 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Settlement Expense	9 Months Ended
Note 13 - Settlement Expense	Sep. 30, 2018
Notes to Financial Statements
Settlement Expense [Text Block]	13 . Settlement expense On June 18, 2018, the Company entered into a Settlement Agreement with the former shareholders of Immunetics, Inc., or the Immunetics Settlement Agreement, to resolve disputes arising from the Agreement and Plan of Merger dated October 12, 2016. The terms of the Immunetics Settlement Agreement are confidential. On June 30, 2017, the Company and Statens Serum Institut, or SSI, entered into a Release and Settlement Agreement, or the SSI Settlement Agreement, to resolve outstanding disputes arising from the license agreement with SSI. The terms of the SSI Settlement Agreement are confidential.